Ark Bio Of China Bets On Untapped Pediatric Antiviral Market Where Few Have Succeeded
Executive Summary
Founded five years ago, Shanghai-based Ark Bio sees big potential in the less crowded pediatric antiviral treatment market. Now the start-up is in Phase II development for its lead asset ziresovir for respiratory syncytial virus (RSV) infection, which was licensed from Roche.
You may also be interested in...
Refocus On China: Ark Bio Evolves As It Plans Shanghai Listing
Shanghai-based Ark Biosciences has expanded its pipeline from the RSV-targeting drug ziresovir, licensed from Roche, to pediatric and fibrosis treatments, where there are largely untapped opportunities in China. In a strategy shift, the company is betting on the domestic market instead of going global.
New Designations Set To Speed Hemlibra, CAR-T In China
China is set to grant priority reviews to major biologics from Roche, the first CAR-T therapy from Wuxi Juno, and breakthrough therapy designation to a pediatric respiratory antiviral from ArkBio.
Coronavirus Notebook: China Focuses On Antivirals As Death Toll Passes SARS
Chief executives of two antiviral and vaccine developers share with Scrip their development plans and projections as the death toll from the coronavirus outbreak reaches 900 with more cases being confirmed worldwide.